|
CZ290470B6
(cs)
|
1991-10-18 |
2002-07-17 |
Monsanto Technology Llc |
5 či 6 členné aromáty jako fungicidy pro kontrolu stéblolamu rostlin, způsob kontroly a fungicidní směs k provedení tohoto způsobu
|
|
SE9703407D0
(sv)
*
|
1997-09-19 |
1997-09-19 |
Astra Ab |
New use
|
|
SE9802073D0
(sv)
|
1998-06-11 |
1998-06-11 |
Astra Ab |
New use
|
|
GB9825554D0
(en)
*
|
1998-11-20 |
1999-01-13 |
Smithkline Beecham Spa |
Novel Compounds
|
|
US7037922B1
(en)
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
ATE247652T1
(de)
|
1999-03-29 |
2003-09-15 |
Neurogen Corp |
4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden
|
|
AU4802500A
(en)
|
1999-04-26 |
2000-11-10 |
Neurogen Corporation |
2-aminoquinolinecarboxamides: neurokinin receptor ligands
|
|
EP1659120A1
(en)
*
|
2001-04-11 |
2006-05-24 |
GlaxoSmithKline S.p.A. |
3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
|
|
WO2002089802A2
(en)
*
|
2001-05-08 |
2002-11-14 |
Schering Corporation |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
DE602004028678D1
(de)
|
2003-01-28 |
2010-09-23 |
Ironwood Pharmaceuticals Inc |
Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
|
|
GB0303086D0
(en)
|
2003-02-11 |
2003-03-19 |
Merck Sharp & Dohme |
New compounds
|
|
GB0419192D0
(en)
|
2004-08-27 |
2004-09-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
SG155229A1
(en)
*
|
2004-11-09 |
2009-09-30 |
Smithkline Beecham Corp |
Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
|
|
GB0425077D0
(en)
*
|
2004-11-12 |
2004-12-15 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0515580D0
(en)
|
2005-07-29 |
2005-09-07 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
JP2009504641A
(ja)
*
|
2005-08-11 |
2009-02-05 |
アストラゼネカ・アクチエボラーグ |
Ｎｋ−３受容体の調節剤としてのアルキルピリジルキノリン
|
|
AR057130A1
(es)
|
2005-09-21 |
2007-11-14 |
Astrazeneca Ab |
Quinolinas de alquilsulfoxido y una composicion farmaceutica
|
|
TW200804288A
(en)
*
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
|
CA2701120A1
(en)
*
|
2007-09-28 |
2009-04-09 |
Glaxosmithkline Llc |
Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
|
|
EA201000392A1
(ru)
*
|
2007-09-28 |
2010-10-29 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
|
|
CA2930674A1
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
JP2011528375A
(ja)
|
2008-07-16 |
2011-11-17 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
KR20220042487A
(ko)
|
2008-12-31 |
2022-04-05 |
알데릭스, 인코포레이티드 |
체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
JP6392754B2
(ja)
|
2012-08-21 |
2018-09-19 |
アーデリクス，インコーポレーテッド |
体液貯留又は塩過負荷に関係する疾患及び消化管疾患の治療におけるｎｈｅ仲介の逆輸送を阻害するための化合物並びに方法
|
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
BR112015025805A2
(pt)
|
2013-04-12 |
2017-07-25 |
Ardelyx Inc |
compostos de ligação de nh3 e métodos para inibir o transporte de fosfato
|
|
WO2014170648A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
EP4424697A3
(en)
|
2013-06-05 |
2024-12-25 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
WO2018129552A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|
|
BR112019013963A2
(pt)
|
2017-01-09 |
2020-04-28 |
Ardelyx Inc |
inibidores de antiporte mediado por nhe
|